Cancer screening

Global Mammography Systems Market (2021 to 2029) - Featuring Hologic, Phillips Healthcare and Toshiba Medical Systems Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 15, 2021
Health, Oncology, Medical devices, Clinical medicine, Medicine, Medical specialties, Biopsy, Cancer screening, Breast imaging, Mammography, Projectional radiography, Breast biopsy, Stereotactic surgery, Breast cancer, Planmed

Factors such as booming healthcare industry with developing healthcare infrastructure and rising investments, government initiatives and mounting awareness regarding regular monitoring and diagnosis are fuelling the global mammography systems market.

Key Points: 
  • Factors such as booming healthcare industry with developing healthcare infrastructure and rising investments, government initiatives and mounting awareness regarding regular monitoring and diagnosis are fuelling the global mammography systems market.
  • The products segment includes screen film mammography, digital mammography systems, analog mammography systems, stereotactic breast biopsy, and 3D mammography systems.
  • To assess the market competition, company profiling and market positioning of leading participants in the global mammography systems have been provided in the report.
  • Company profiling of major market players is done based on business overview, financial analysis, product portfolio and key recent developments of each company operating in the mammography systems market.

NanoString and Parker Institute for Cancer Immunotherapy Collaborate to Optimize Cell Therapies to Treat Cancer

Retrieved on: 
Tuesday, June 15, 2021
Oncology, Health, Genetics, General Health, Research, Science, Biotechnology, Clinical medicine, Medicine, Health sciences, Cancer screening, NanoString Technologies, Immunotherapy, Cancer, the Parker Institute for Cancer Immunotherapy, NanoString Technologies, Inc., THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY, NANOSTRING TECHNOLOGIES, INC.

The technology utilizes a standardized gene expression panel of 780 genes, which the team will use to profile eight different biological characteristics of existing cell therapies.

Key Points: 
  • The technology utilizes a standardized gene expression panel of 780 genes, which the team will use to profile eight different biological characteristics of existing cell therapies.
  • Overcoming these barriers can help unlock the benefits of cellular therapies for cancer patients currently in need of more effective treatments.
  • The Parker Institute for Cancer Immunotherapy (PICI) is radically changing the way cancer research is done.
  • NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Kheiron’s AI Breast Screening Solution Mia® Receives Regulatory Clearance in Australia and New Zealand

Retrieved on: 
Tuesday, June 15, 2021
Biotechnology, Other Health, Health, Radiology, Oncology, Cancer screening, Breast imaging, Mammography, Projectional radiography, Breast cancer, Clinical medicine, Medicine, Health, Biotechnology, Other Health, Health, Radiology, Oncology, Cancer screening, Breast imaging, Mammography, Projectional radiography, Breast cancer, Clinical medicine, Medicine, Health, Kheiron Medical Technologies, AI Advance, KHEIRON MEDICAL TECHNOLOGIES, AI ADVANCE

Mia is being launched in partnership with AI Advance , an AI consulting services and software distribution company for the medical imaging industry based in Australia and New Zealand.

Key Points: 
  • Mia is being launched in partnership with AI Advance , an AI consulting services and software distribution company for the medical imaging industry based in Australia and New Zealand.
  • Our mission at Kheiron is to support breast screening professionals in the fight against breast cancer with proven and effective AI-enabled tools, states Alex Hamlow, Kheirons chief commercial officer.
  • Were excited that Mia is the first AI independent reader solution available for use within the breast screening community in Australia and New Zealand.
  • We are looking forward to bringing the Mia solution to the breast screening community throughout Australia and New Zealand, comments Peter Rady, director and co-founder of AI Advance.

iCAD’s ProFound AI for Digital Breast Tomosynthesis Version 3.0 Receives CE Mark Approval

Retrieved on: 
Monday, June 14, 2021
Breast cancer, Tomosynthesis, X-ray computed tomography, DBT, Cancer screening, Health, Breast imaging, Clinical medicine, Ontology

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ProFound AI Version 3.0 for Digital Breast Tomosynthesis (DBT) received CE Mark approval.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ProFound AI Version 3.0 for Digital Breast Tomosynthesis (DBT) received CE Mark approval.
  • Built with the latest in deep-learning technology, ProFound AI for DBT Version 3.0 rapidly analyzes each tomosynthesis image, detecting malignant soft tissue densities and calcifications with unrivaled accuracy.
  • Since obtaining CE Mark certification with our first generation of this technology in July 2019, ProFound AI has been installed in a growing number of medical imaging centers across Europe.
  • ProFound AI is fully in line with this desire to constantly improve radiologists abilities to detect breast cancer as early as possible.

Tower Radiology Expands 3D Mammography to West Pasco County

Retrieved on: 
Monday, June 7, 2021
Medicine, Cancer screening, Clinical medicine, Breast imaging, Medical imaging, Breast cancer, Medical tests, Mammography, Projectional radiography, Radiology, Magnetic resonance imaging, Pasco County, Florida

TAMPA, Fla., June 7, 2021 /PRNewswire-PRWeb/ -- Tower Radiology has expanded 3D mammography (Tomosynthesis) into West Pasco County with its addition at our New Port Richey location at 5539 Marine Pkwy., New Port Richey, FL 34652.

Key Points: 
  • TAMPA, Fla., June 7, 2021 /PRNewswire-PRWeb/ -- Tower Radiology has expanded 3D mammography (Tomosynthesis) into West Pasco County with its addition at our New Port Richey location at 5539 Marine Pkwy., New Port Richey, FL 34652.
  • Patients who benefit most from 3D mammography are those who have dense breasts, but women with non-dense breasts can also benefit in the same ways.
  • Established in 1992, Tower Radiology provides quality radiology services in a comfortable, convenient, outpatient setting throughout Hillsborough, Pasco and East Pinellas Counties.
  • Accredited by the American College of Radiology, Tower offers specialized services such as 3D mammography, high field wide-bore MRI, weight-bearing open MRI, extremity open MRI, cardiac MRI, CT low-dose lung screening and PET/CT.

Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer

Retrieved on: 
Friday, June 4, 2021
Health, Genetics, Science, Other Science, Oncology, Clinical medicine, Medicine, Health, Infectious causes of cancer, Cancer screening, Colorectal cancer, Cancer, Biopsy, Liquid biopsy, Helmy Eltoukhy, Richard B. Lanman

Guardant Health, Inc. (Nasdaq: GH) presents new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-June 8, 2021, showing that its LUNAR-2 blood test is a highly sensitive test that can detect colorectal cancer (CRC) in early-stage cancer patients.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH) presents new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-June 8, 2021, showing that its LUNAR-2 blood test is a highly sensitive test that can detect colorectal cancer (CRC) in early-stage cancer patients.
  • Its great to see the momentum Guardant Health has achieved since the introduction of their best-in-class liquid biopsy technology in 2014.
  • Now, they are at the precipice of delivering a highly sensitive colorectal cancer screening test, and I look forward to seeing the outcome of their registrational study.
  • Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal test for early-stage cancer patients.

GRAIL Presents Interventional PATHFINDER Study Data at 2021 ASCO Annual Meeting and Introduces Galleri, a Groundbreaking Multi-Cancer Early Detection Blood Test

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Practice Management, Other Health, Health, General Health, Oncology, Medical devices, Research, Hospitals, Science, Clinical trials, Grail, Cancer screening

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today presented the first results from the interventional PATHFINDER study evaluating Galleri, a multi-cancer early detection (MCED) blood test.

Key Points: 
  • GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today presented the first results from the interventional PATHFINDER study evaluating Galleri, a multi-cancer early detection (MCED) blood test.
  • The results, presented at the 2021 ASCO Annual Meeting, support Galleris performance in clinical settings.
  • These results are a pivotal step toward extending early detection to many more types of cancer.
  • GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection.

Izotropic Updates Timelines for Clinical Study and Fabrication of Initial Izoview Units

Retrieved on: 
Thursday, June 3, 2021
Clinical medicine, Medicine, Cancer screening, Breast imaging, Projectional radiography, Mammography, Radiology, Health, Breast cancer, CT scan

As a result, now going into the initial clinical study comparing Izoview with diagnostic mammography, Izotropic expects to deliver a better performing system, with a subsequent broader product offering and a more competitively priced Breast CT system.

Key Points: 
  • As a result, now going into the initial clinical study comparing Izoview with diagnostic mammography, Izotropic expects to deliver a better performing system, with a subsequent broader product offering and a more competitively priced Breast CT system.
  • The purpose of the clinical study is to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures.
  • Details of the initial clinical study and study partners will be issued in a press release prior to the commencement of the study.
  • Due to the Covid-19 pandemic and the material adjustments to the initial business plan, the Company's timeline projections for clinical development have changed.

Motus GI Announces Publication of Pure-Vu® System Clinical Data in Peer-Reviewed Journal BMC Gastroenterology

Retrieved on: 
Thursday, June 3, 2021
Clinical medicine, Medicine, Cancer screening, Large intestine, Colonoscopy, Diagnostic gastroenterology, Endoscopy, Forward-looking statement

Among the important findings that the Company continues to emphasize since the data from the REDUCE study were first announced is the Pure-Vu systems 97% clinical success rate.

Key Points: 
  • Among the important findings that the Company continues to emphasize since the data from the REDUCE study were first announced is the Pure-Vu systems 97% clinical success rate.
  • Evaluation of the data from our REDUCE study continues to support our belief that the Pure-Vu System can significantly improve bowel preparation quality in hospitalized subjects undergoing colonoscopy.
  • The article covers clinical data from the REDUCE study.
  • Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

Sysmex Inostics presents data at ASCO showing HPV-SEQ, a new CLIA-validated SafeSEQ NGS HPV16/18 liquid biopsy assay, is highly effective for measuring HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OP

Retrieved on: 
Wednesday, June 2, 2021
Clinical medicine, Medicine, Cancer, Infectious causes of cancer, Papillomavirus, Polymerase chain reaction, Cancer screening, Biopsy, Liquid biopsy, Digital polymerase chain reaction, Human papillomavirus infection

The ASCO presentation coincides with the launch of HPV-SEQ as the newest CLIA validated assay in the Sysmex Inostics portfolio of ultra-sensitive SafeSEQ NGS panels.

Key Points: 
  • The ASCO presentation coincides with the launch of HPV-SEQ as the newest CLIA validated assay in the Sysmex Inostics portfolio of ultra-sensitive SafeSEQ NGS panels.
  • Sysmex Inostics has introduced HPV-SEQ, an ultra-sensitive blood-based liquid biopsy solution for identifying and accurately quantifying circulating HPV 16 and HPV 18 DNA in patients with HPV-related cancers.
  • Importantly, a high correlation was observed between dynamic changes in patients' cfHPV DNA levels and radiographic responses following induction therapy.
  • Sysmex Inostics, a Sysmex Corporation subsidiary, empowers discoveries in oncology by providing investigators cost-effective and ultra-sensitive quantitative liquid biopsy solutions, OncoBEAM (digital PCR) and SafeSEQ (NGS).